Valproic acid suppresses Nrf2/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells-Reference-Cited by-同舟云学术

Valproic acid suppresses Nrf2/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells

Published:2014-04 Issue: Volume:121 Page:26-34
ISSN:0014-4835
Container-title:Experimental Eye Research
language:en
Short-container-title:Experimental Eye Research

Author:

Palsamy Periyasamy,Bidasee Keshore R.,Shinohara Toshimichi^ORCID

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Reference62 articles.

1. Image processing with ImageJ;Abramoff;Biophot. Int.,2004

2. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo;Achachi;Proc. Natl. Acad. Sci. U. S. A.,2005

3. Activation of calpain in lens: a review and proposed mechanism;Azuma;Exp. Eye Res.,1997

4. Presenile cataracts in phenytoin-treated epileptic patients;Bar;Arch. Ophthalmol.,1983

5. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs;Barbon;Biol. Psychiatry,2006

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulation of keap-1/Nrf2/HO-1 and NF-ĸb/caspase-3 signaling pathways by dihydromyricetin ameliorates sodium valproate-induced liver injury;Archives of Biochemistry and Biophysics;2024-08

2. Unexpected Cataract Formation Following Valproate Treatment: A Case Report;Cureus;2024-06-25

3. Valproate Mediated Proteasome Dysfunctions Induce Apoptosis;Advanced Therapeutics;2024-05-21

4. Valproic Acid Causes Redox-Regulated Post-Translational Protein Modifications That Are Dependent upon P19 Cellular Differentiation States;Antioxidants;2024-05-01

5. Three Decades of Valproate: A Current Model for Studying Autism Spectrum Disorder;Current Neuropharmacology;2024-02